Ranbaxy: Exports cross target - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy: Exports cross target

Dec 12, 2001

Ranbaxy has announced that it’s two wholly owned subsidiary in the US viz, Ohm Laboratories and Ranbaxy Pharmaceuticals Inc, have already achieved sales in excess of US $ 100 m. This would represent a remarkable growth of more than 65% from the US markets. Cumulatively both the subsidiaries are likely to close the year (Dec’01) with revenues in the range of US $ 105-110 m. It is also for the first time that Ranbaxy’s international operations on a cumulative basis would turn profitable. The revenue mix of the company would tilt heavily in favour of exports. Exports are expected to contribute around 63% of the company’s revenues in the current year as compared to 48% last year.

This outstanding performance seems to be fuelled by generic launch of Ibuprofen (combination) and Lorazepam in September’01. The Ibuprofen combination was the first successful Para IV approval from Ranbaxy’s stable. On the other hand Lorazepam is an anti-anxiety drug with market size close to US $ 400 m.

Other geographies, where Ranbaxy has a direct presence are also logging impressive numbers. With this, the company should be able to complete the current financial year in excess of its target of US $ 600 m in global revenues. An expanding product basket, mature ANDA filings and further penetration in large pharma markets could ensure sustainable growth for Ranbaxy, going forward.

Unlike other pharma companies, Ranbaxy has not restricted itself to the US markets and has positioned itself as an integrated player in the export markets. Again unlike others, Ranbaxy has invested huge sums in creating a direct presence in 25 countries across the globe through various subsidiaries. Apart from US, the company has identified UK, Brazil, China and Germany as its core markets and is working towards penetrating these markets.

We are marginally upgrading our sales target for Ranbaxy in view of this remarkable performance. At the current market price of Rs 757, the stock trades at 26x expected earnings for FY02 (Year ending Dec’01).

Equitymaster requests your view! Post a comment on "Ranbaxy: Exports cross target". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks